
REVIVEBIO to debut next-generation probiotics-derived exosome and commercial application
Taiwanese biotech firm REVIVEBIO Co is set to launch the first commercial application of its next-generation probiotics (NGPs)-derived exosome by end-October.
News & Analysis on Cosmetics Innovation
Taiwanese biotech firm REVIVEBIO Co is set to launch the first commercial application of its next-generation probiotics (NGPs)-derived exosome by end-October.